Veracyte, Inc.
VCYT
Updated: 24/09/2026, 00:57:20
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
No summaries found.
- Share price
- $43.82
- Market cap
- $3.50B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Marc Stapley
- Employees
- 755
- IPO date
- 29/10/2013
- Beta
- 1.926
- Last dividend
- $0.00
- Day range
- $42.25 – $43.86
- 52-week range
- $29.46 – $60.91
- 1-day performance
- 1.06%
- 1-year performance
- 48.77%
- Current drawdown (1Y)
- -28.06%
- CIK
- 0001384101
- CUSIP
- 92337F107
- ISIN
- US92337F1075
- Created
- 07/12/2025, 14:56:26
- Last update
- 24/09/2026, 00:57:20
Track Veracyte, Inc. with an AI analyst
See which prediction-market events move VCYT, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
Zacks Investment Research • STOCK • 11/06/2026, 12:52:09
Needham Analyst Raises Price Target for Veracyte (NASDAQ: VCYT) Amidst Diagnostic Test Advancements
Market Data • Market Data • 01/06/2026, 20:10:50
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
Seeking Alpha • STOCK • 01/06/2026, 19:14:08
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
Business Wire • STOCK • 29/05/2026, 17:15:00
Veracyte: The Evidence Flywheel Is Turning Into A Cash Flow Platform
Seeking Alpha • STOCK • 28/05/2026, 07:17:46
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now?
Zacks Investment Research • STOCK • 27/05/2026, 14:11:15
Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?
Zacks Investment Research • STOCK • 25/05/2026, 14:20:16
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
Zacks Investment Research • STOCK • 25/05/2026, 12:51:10
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
Business Wire • STOCK • 21/05/2026, 20:00:00
Why Veracyte Stock Is Skyrocketing Higher This Week
The Motley Fool • STOCK • 08/05/2026, 02:51:25
Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors
Zacks Investment Research • STOCK • 07/05/2026, 12:31:34
Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 06/05/2026, 00:51:14